The two directors purchased a combined $74,000+ worth of shares this week.
Showing 25 of 2948
Progenza is the company’s lead cell therapy technology platform.
Analysis of final results from a drilling campaign show feedstock can be used to produce HPA of 99.99% or greater.
Estimated size of the osteoarthritis treatment market is US$5 billion per annum.
The company recently appointed Canadian Luke Pigeau as master grower.
The C$5 million investment gives MMJ a 6.9% interest in MediPharm Labs Inc.
The company aims to mine and process its kaolin into high-purity alumina (HPA).
Race Oncology's shares are currently in pre-open pending the update.
Canada will be the largest developed nation to legalise nationwide recreational use.
Imugene is a clinical stage immuno-oncology company.
BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis.
eSense is aiming to commercialise its formulations into the global e-cigarette liquid market.
Paragon has been acquiring businesses in the healthcare sector.
Two girls in France have had a successful response to the treatment with Bisantrene.
Imugene is an immuno-oncology company focused on gastric cancer.
Admedus is a medical technologies company with numerous catalysts on the horizon.
Compumedics is monetising its sleep technology in China.
CannPal is researching the benefits of medical cannabis for companion animals.
Shares in Compumedics are expected to resume trade on Thursday.
All Kiwi Buy stores are operating profitably post labour and occupancy expenses.
A daigou buys consumer goods abroad on behalf of people living in China.
Important addition to the company's current European and global IP portfolio.
The company has filed three new provisional patent applications in the US.
The agreement follows a successful, revenue-generating launch of cannaQIX® in Switzerland and Lichtenstein.
The single tranche placement will see new shares issued priced at 3.4 cents.